Clinical Trial Ceftriaxone in Subjects With ALS

• Status: Completed
• Trial end date: 2012-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to evaluate the safety and efficacy of ceftriaxone treatment in amyotrophic lateral sclerosis (ALS).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Massachusetts General Hospital
• Collaborator: National Institute of Neurological Disorders and Stroke (NINDS)
• Treatments: Ceftriaxone; Cephalosporins

Criteria

Inclusion Criteria:

• Participants will be people with ALS, at least 18 years of age.

• Participants must be medically able to undergo the study procedures and have a caregiver or other individual who will be available to help with daily study medication administration.

• Participants should live within a reasonable distance of the study site, due to frequent study visits.

Exclusion Criteria:

• Participants cannot be taking any other experimental medications for ALS, or have a history of sensitivity to cephalosporin antibiotics (such as Ancef, Keflex, Ceclor, Ceftin, Lorabid, Suprax, or Fortaz).